Overall, pre-clinical results indicate that SSD and its active constituents inhibit BC development via preventing ERK1/2 phosphorylation, activating p38 phosphorylation, and modulating the expression of the MAPK pathway. The gene discussed is MAPK3; the disease is breast cancer.